Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine
Clinical trial NCT04833101 · COMPLETED
Trial details
- NCT number
- NCT04833101
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-07
- Primary completion
- 2021-09-18
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.